| abstract |
Osteogenesis promoting agents characterized by containing a compound having an Rho kinase inhibitory activity and a bone inducing factor; and osteogenesis induction potentiating agents characterized by containing a compound having an Rho kinase inhibitory activity as the active ingredient and being capable of potentiating the bone inducing effect of a foreign bone inducing factor. As an example of the compound having an Rho kinase inhibitory activity, (+)-trans-4-(1-aminoethyl)-1-(4-puridylcarbamoyl)cyclohexane may be cited. By using the compound having an Rho kinase inhibitory activity together with the bone inducing factor, the differentiation of mesenchymal cells into osteoblasts is more remarkably induced. The above-described osteogenesis promoting agents and osteogenesis induction potentiating agents are useful in preventing and treating various bone diseases, in particular, bone or cartilage injury, defect or hypogenesis. |